Gilead Sciences, Inc. (Nasdaq: GILD) announced new research to be presented at The Liver Meeting ® 2024, hosted by the American Association f...
Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidne...
INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced a contra...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Comm...
Agilent Technologies Inc. (NYSE: A) announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infi...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open lette...
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearanc...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo&r...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new results from a Phase 2 clin...
Amicus Therapeutics (Nasdaq: FOLD) announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmace...
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and o...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of positive results from the Phase 2b/3 clinical trial ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, announced the submission of a Type II Variatio...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
© 2025 Biopharma Boardroom. All Rights Reserved.
